A Parkinson’s treatment developed by Cambridge gene therapy firm Voyager Therapeutics helped patients improve motor function in a small, early-stage study, the company said Wednesday.
Voyager (Nasdaq: VYGR), part of a new wave of gene editing firms in Massachusetts, released positive interim data from a Phase 1b trial of the treatment, which involves drilling a hole into a patient’s skull and infusing a gene that helps to produce dopamine. Parkinson’s kills off important nerve cells that generate…
↧